HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
IPO Year: 2022
Exchange: NASDAQ
Website: https://www.hillevax.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/9/2024 | $28.00 → $2.00 | Outperform → Market Perform | Leerink Partners |
| 7/9/2024 | $34.00 → $3.00 | Buy → Hold | Stifel |
| 7/9/2024 | $28.00 → $2.00 | Buy → Neutral | H.C. Wainwright |
| 7/8/2024 | Buy → Neutral | Guggenheim | |
| 7/8/2024 | $24.00 → $5.00 | Overweight → Neutral | JP Morgan |
| 12/13/2023 | $28.00 | Buy | H.C. Wainwright |